Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27889000 | 0.86 | ITGA4 (0.33) | ITGA4ITGB7HCAR2 | |
| SCHEMBL13386460 | 0.77 | HDAC6 (0.38) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2986859 | 0.75 | VNN1 (0.39) | VNN1 | |
| Trifluoroacetic Acid SCHEMBL2432015 | 0.68 | HCAR2 (0.37) | ITGA4ITGB7HCAR2 | |
| SCHEMBL30599582 | 0.66 | VNN1 (0.42) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL27905673 | 0.60 | P2RX7 (0.32) | — | |
| SCHEMBL17223345 | 0.59 | KDM1A (0.40) | — | |
| SCHEMBL17223535 | 0.59 | KDM1A (0.40) | — | |
| SCHEMBL17223485 | 0.59 | KDM1A (0.40) | — | |
| SCHEMBL21408730 | 0.59 | PLOD2 (0.67) | HDAC3HDAC1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545050-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2545050-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HDAC3 1270/4885HDAC1 2303/4885HDAC2 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.